Tag Archives: cardiometabolic health

Poor medication persistence remains one of the hardest barriers to long-term blood pressure control. For people with diabetes, the stakes are especially high because hypertension adds to cardiovascular and kidney risk. Now, research into RNAi for hypertension in people with diabetes is raising an intriguing possibility: could an injection given …

The treatment landscape for type 2 diabetes has changed dramatically over the past decade. While selective SGLT2 inhibitors have become a cornerstone of diabetes management because of their proven cardiovascular and kidney benefits, researchers are now exploring the added potential of dual SGLT1/2 inhibitor therapy for people with diabetes. By …

For decades, A1C has served as the gold standard for assessing long-term glucose control in people with diabetes. However, it tells only part of the story. Researchers are now exploring whether metabolic flexibility could become an important biomarker in diabetes, offering a deeper understanding of metabolic health than A1C alone. …

Depression and diabetes management often overlap in ways that make treatment decisions more complicated. Patients with type 2 diabetes frequently experience depression, and depression can make daily self-care harder. However, some commonly prescribed antidepressants and psychotropic medications may contribute to weight gain, worsen insulin resistance, or complicate long-term metabolic control. …

A bleeding gumline might seem like a minor dental issue, but researchers are increasingly finding that it can signal much more than a need to floss. Chronic inflammation inside the mouth may influence blood sugar control, cardiovascular health, and even long-term diabetes outcomes. As evidence continues to grow, healthcare providers …

The rapid rise of GLP-1 receptor agonists has transformed diabetes treatment and obesity management over the past decade. However, high prices and limited insurance coverage continue to restrict access for many patients. As patents evolve and global pharmaceutical markets shift, conversations about lower-cost GLP-1 therapies are gaining momentum. Clinicians are …

What if the biggest missed opportunity in diabetes care is not a new drug, but when we start using it? Early GLP-1 therapy is gaining attention as clinicians rethink traditional treatment timelines. Instead of reserving GLP-1 receptor agonists for later stages, emerging evidence suggests starting sooner may improve outcomes and …

Choosing the right treatment for patients with both diabetes and heart disease can feel like walking a tightrope. With evolving evidence, the role of incretin therapy in cardiovascular disease management is now at the center of clinical decision-making. Recent cardiovascular outcomes trials have shifted how clinicians think about therapy selection, …

The rise of oral GLP-1 medications is changing how clinicians approach type 2 diabetes treatment. But what if one of the biggest barriers, strict dosing requirements, suddenly disappeared? A newly approved oral option without food or water restrictions is making that question very real. As a result, clinicians now have …

In recent years, the role of incretin therapy in cardiovascular disease management has gained attention as new outcomes data reshape how clinicians approach high-risk patients. But should treatment choices really change based on these findings? As evidence evolves, many providers are reconsidering which therapies deliver both glycemic control and cardiovascular …